{
  "findings": [
    {
      "id": "Q01",
      "metric": "Fraction of tumor proteins represented in immunopeptidome",
      "value": "62.3%",
      "comparator_or_baseline": "37.3% (comparator)",
      "interpretation": "Intratumoral mRNA vaccination was associated with a broader set of tumour proteins being represented in the immunopeptidome.",
      "evidence_line_refs": [
        "L28"
      ]
    },
    {
      "id": "Q02",
      "metric": "Fraction of proteins represented in MHC-I peptidome",
      "value": "40.6%",
      "comparator_or_baseline": "20.6% (comparator)",
      "interpretation": "The MHC-I-presented peptide landscape expanded in the condition described for mRNA vaccination, consistent with increased antigen presentation.",
      "evidence_line_refs": [
        "L29"
      ]
    },
    {
      "id": "Q03",
      "metric": "Retrospective human survival comparison p-value",
      "value": "p=0.01",
      "comparator_or_baseline": "Not applicable (p-value reported for vaccinated vs unvaccinated comparison)",
      "interpretation": "In the retrospective metastatic cohort receiving ICI treatment, prior SARS-CoV-2 mRNA vaccination status was associated with improved survival (reported p=0.01).",
      "evidence_line_refs": [
        "L30"
      ]
    },
    {
      "id": "Q04",
      "metric": "Type I interferon response score (normalized units)",
      "value": "3.1",
      "comparator_or_baseline": "1.0 (baseline/comparator)",
      "interpretation": "Tumours showed a marked induction of a type I interferon response after intratumoral mRNA vaccination according to the normalized score reported.",
      "evidence_line_refs": [
        "L31"
      ]
    },
    {
      "id": "Q05",
      "metric": "PD-L1 expression fold-change in tumor tissue",
      "value": "2.4x",
      "comparator_or_baseline": "1.0x (baseline/comparator)",
      "interpretation": "PD-L1 expression increased in tumour tissue, potentially increasing the relevance of targeting the PD-L1 axis with checkpoint blockade.",
      "evidence_line_refs": [
        "L32",
        "L45"
      ]
    },
    {
      "id": "Q06",
      "metric": "Intratumoral CD8+ T-cell density fold-change",
      "value": "1.8x",
      "comparator_or_baseline": "1.0x (baseline/comparator)",
      "interpretation": "The combination context reported increased CD8+ T-cell density in tumours, consistent with enhanced immune infiltration.",
      "evidence_line_refs": [
        "L33"
      ]
    }
  ],
  "controls_or_null_results": [
    {
      "statement": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
      "evidence_line_ref": "L36"
    },
    {
      "statement": "ICI-only treatment had limited activity in low-immunogenic baseline settings.",
      "evidence_line_ref": "L37"
    },
    {
      "statement": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
      "evidence_line_ref": "L38"
    },
    {
      "statement": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
      "evidence_line_ref": "L39"
    }
  ]
}
